At Nanovery, their cutting-edge DNA nanorobots are revolutionising the biotechnology landscape. As pioneers in nucleic acid nanorobotics (NANs), our platform is the first to provide comprehensive solutions for RNA therapeutic analysis and biomarker quantification. This innovation elevates research precision and simplifies testing protocols.
Their mission is to make the testing processes as simple as possible to drive advancements in biotech research. Nanovery's NANs technology is not just part of biotechnology's future; it is actively shaping it, ensuring their partners stay at the forefront of innovation.
Precision for Medicine, Oncology and Rare Disease is proud to offer the first comprehensive, fully integrated clinical development solution. We are devoted exclusively to oncology and rare disease, and our teams are passionate about improving the lives of these patients. By combining the progressive science of biomarkers and analytics with our excellence in complex clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.
Contact Precision for Medicine, Oncology and Rare Disease via their website
PrecisionLife is built upon a collective ambition to improve our understanding of complex diseases and create better, more personalized therapy options so that we can help patients to live longer, healthier lives.
The PrecisionLife® platform takes a radical new approach to analysis of complex disease biology based on a wide range of patients’ genomic, clinical, and epidemiological data, enabling the discovery of richer and more useful links between patients, disease sub-groups, targets and drugs.
Our powerful patented data analytics and decision support platforms are built on a unique mathematical framework and deep experience in delivering innovative new technologies and products.
Headquartered near Oxford in the UK, we also have offices in the USA, Denmark and Poland.
